(firstQuint)Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients.

 Stage I: To evaluate the safety of administering TR002 to liver transplant recipients.

 Stage II: To evaluate the efficacy of TR002 administration in allowing for the discontinuation of immunosuppressive therapy in liver transplant recipients.

.

 Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients@highlight

'ThRIL' aims to explore the feasibility, safety and efficacy of TR002, a regulatory cell therapy, as adjunct immunosuppressive treatment in the context of liver transplantation